Ardelyx (ARDX) Non-Current Assets (2013 - 2026)
Ardelyx's (ARDX) quarterly Non-Current Assets came in at $122.6 million in Q1 2026, up 25.78% YoY from $97.5 million in Q1 2025, and up 2.81% on a QoQ basis from $119.3 million in Q4 2025.
Ardelyx (ARDX) Non-Current Assets (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Non-Current Assets data on file, last reported at $122.6 million in Q1 2026.
- Quarterly Non-Current Assets rose 25.78% year-over-year to $122.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $475.3 million (up 39.37% YoY) and the FY2025 annual result came in at $119.3 million, up 50.42% from the prior year.
- Non-Current Assets improved to $122.6 million in Q1 2026, from $119.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $122.6 million in Q1 2026 to a low of $15.2 million in Q1 2022.
- A 5-year average of $70.2 million and a median of $79.3 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 5.34% — and 2023, when it jumped 229.13%.
- Tracing ARDX's Non-Current Assets over 5 years: stood at $36.5 million in 2022, then jumped by 41.15% to $51.5 million in 2023, then jumped by 54.08% to $79.3 million in 2024, then soared by 50.42% to $119.3 million in 2025, then increased by 2.81% to $122.6 million in 2026.
- The last three Non-Current Assets figures came in at $122.6 million (Q1 2026), $119.3 million (Q4 2025), and $118.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 133.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.97 Mn |
| Mar 31, 2026 | 122.64 Mn |
| Dec 31, 2025 | 119.29 Mn |
| Sep 30, 2025 | 118.19 Mn |
| Jun 30, 2025 | 115.20 Mn |
| Mar 31, 2025 | 97.50 Mn |
| Dec 31, 2024 | 79.30 Mn |
| Sep 30, 2024 | 83.77 Mn |
| Jun 30, 2024 | 80.47 Mn |
| Mar 31, 2024 | 84.44 Mn |
| Dec 31, 2023 | 51.47 Mn |
| Sep 30, 2023 | 48.16 Mn |
| Jun 30, 2023 | 49.09 Mn |
| Mar 31, 2023 | 49.97 Mn |
| Dec 31, 2022 | 36.46 Mn |
| Sep 30, 2022 | 24.80 Mn |
| Jun 30, 2022 | 17.50 Mn |
| Mar 31, 2022 | 15.18 Mn |
| Dec 31, 2021 | 16.26 Mn |
| Sep 30, 2021 | 17.47 Mn |